In this study, we took advantage of the robust clinical EHR and genotype data from the largest and diverse NAFLD case/control cohort to date to develop a non-invasive ALT-based NAFLD phenotype that may be used in future, large-scale population-based studies. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.